<DOC>
	<DOCNO>NCT01240850</DOCNO>
	<brief_summary>Chronic periaortitis clinico-pathological entity encompass idiopathic retroperitoneal fibrosis perianeurysmal retroperitoneal fibrosis . The treatment disease generally base use glucocorticoid , often effective . However , prolong steroid treatment usually need achieve sustain remission ; additionally , patient frequently develop disease relapse follow treatment discontinuation , therefore may expose high cumulative dos glucocorticoid . Preliminary data report literature show methotrexate may effective combination prednisone retroperitoneal fibrosis . In addition , methotrexate often use steroid-sparing agent different inflammatory disease . The aim study evaluate whether treatment low-dose prednisone plus methotrexate non-inferior conventional dose-prednisone achieve remission retroperitoneal fibrosis patient .</brief_summary>
	<brief_title>Methotrexate Steroid-sparing Agent Idiopathic Retroperitoneal Fibrosis : Randomised , Multicenter Trial</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Retroperitoneal Fibrosis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>New diagnosis idiopathic retroperitoneal fibrosis chronic periaortitis ; write informed consent Secondary form retroperitoneal fibrosis ( e.g . drug , surgery , neoplasms , infection ) Previous medical therapy retroperitoneal fibrosis Renal failure creatinine &gt; 2 mg/dl prove reversible ureteral decompression Hypersensitivity study drug Pregnancy Active infection malignant neoplasm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Retroperitoneal fibrosis</keyword>
	<keyword>Inflammatory aneurysm</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Aorta</keyword>
</DOC>